Conflict of interest
Author(s):
Guidelines commissioned by
Last modified:
30 January 2014 00:53:15
Competing interest declarations and management
Working Party Members were asked to declare in writing, any interests relevant to the guideline development, prior to commencement. Members were asked to update their information if they became aware of any changes to their interests.
All declarations were added to a register of interests as listed below. The register was made available to the Working Party throughout the development of the guideline, allowing members to take any potential conflicts of interest into consideration during discussions, decision making and formulation of recommendations.
If Working Party Members were identified as having a significant real or perceived conflict of interest, the Chair could decide that the member either leave the discussion whilst the specific area they were conflicted in was discussed or the member could remain present but not participate in the discussion, or decision making on the specific area where they were conflicted. There were no instances where this occurred during the development of this guideline.
The guidelines have now entered the updating phase. Guideline working party members are responsible to update their conflict of interest statements if a new interest arises. The members will receive a formal reminder to review their statements and ensure it is up-to-date prior to the yearly meetings that will be scheduled to review all updates.
| Working party member | Competing interest declaration |
|---|---|
| Annabel Pollard RN, BA, Grad. Dip App Psych, M Psych (Clinical) MAPS | No competing interest to declare. |
| Assoc. Prof. Nick Pavlakis | Lung Cancer Advisory Boards: Lilly, Merck-Sereno, Roche, Astra-Zeneca, Boehringer Ingelheim
Speaking Honoraria: Lilly, Roche, Merck-Sereno, Pfizer, Boehringer Ingelheim |
| Associate Professor Christos Karapetis | Advisory Role – Merck, Roche, BMS, Astra Zeneca, MSD
Sponsorship to attend Scientific Professional Oncology Society Meetings – Eli Lilly, Roche, Astra Zeneca, BMS, Merck Serono |
| Associate Professor Gavin Wright MD FRACS PhD | Received an Infrastructure and Educational grant to run a VATS lobectomy course provided by Covidien. Has not received financial benefit personally. |
| Associate Professor Josephine Clayton MBBS PhD FRACP FAChPM | No competing interest to declare. |
| Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACP | No competing interest to declare. |
| Associate Professor Shalini Vinod MBBS MD FRANZCR | No competing interest to declare. |
| Caitlin Broderick | To be confirmed |
| Di Saward | No competing interest to declare. |
| Dr Adelaide Morgan | To be confirmed |
| Dr Alesha Thai | To be confirmed |
| Dr Dish Herath (Gunawardana) | Received funding from Lilly and Roche to attend scientific meetings.
Received funding from Roche to conduct a pilot EGFR testing program in patients. |
| Dr Jeremy Ruben MBBCh (Hons), FCRadOnc (SA), FRANZCR, Mmed, MD (Monash) | No competing interest to declare |
| Dr Margot Lehman MBBS FRANZCR GDP | No competing interest to declare |
| Dr Maria Ftanou BAppSc(Hons) Dpsych Clinical | No competing interest to declare. |
| Dr Melissa Moore BA BSC MBBS (Hons) FRACP PhD | To be confirmed |
| Dr Natasha Michael MBChB MRCP MRCGP MSC | No competing interest to declare. |
| Dr Shawgi Sukumaran | To be confirmed |
| Dr Stephen Barnett | No competing interest to declare |
| Dr Suzanne Kosmider | Nil |
| Dr Toni Pearson | To be confirmed |
| Dr Tracy Smith BSc, MBBS, FRACP, Clin Dip Pall Med | No competing interest to declare |
| Gary Hammerschlag BSc, MBBS, FRACP | To be confirmed |
| Mary Duffy | To be confirmed |
| Matthew Grant MBBS, FRACGP, MBioethics, DipPallMed | To be confirmed |
| Merlina Sulistio MBBS BMedSc FRACP (palliative medicine) | To be confirmed |
| Mustafa Khasraw MBChB MD MRCP FRACP | Received sponsorship from Roche, Novartis and Sanofi-Aventis to attend scientific meetings.
Received a grant from Merck Serono to conduct a clinical trial. Involved as a consultant and in an advisory capacity by Roche. Nature of input: appraised literature regarding role of chemotherapy in stage IV lung cancer. |
| Prof Matthew Peters MD FRACP | No competing interest to declare in the currency of the Working Group that are directly relevant to its work in the nominated time span.
Received honoraria for CME lectures from AstraZeneca and Boehringer Ingelheim for presentations not related to lung cancer. |
| Professor David Ball MB BS, MD, FRANCZR | Sat on Advisory Boards for the following companies during 2010-2011:
Lilly Oncology, Boehringer- Ingelheim,Astra Zeneca and Pfizer. Received funding to attend ASCO Chicago 2010 from Boehringer-Ingelheim. |
| Professor Michael Brown MBBS PhD FRACP FRCPA | Melanoma Advisory Boards for GSK, BMS, and Roche
Prostate Cancer Advisory Board for Bayer Research support from Novartis Travel sponsorship from Eli Lilly Educational grant from BMS |